搜索
 > 【CD74】重组蛋白信息

CD74信息

英文名称:HLA-DR antigens-associated invariant chain
中文名称:HLA-DR抗原相关不变链
靶点别称:HLA-DR antigens-associated invariant chain,Ia antigen-associated invariant chain,Ii,CD74,HLA class II histocompatibility antigen gamma chain,p33,CD_antigen=CD74,DHLAG
上市药物数量:0
临床药物数量:8
最高研发阶段:临床二期

CD74产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
CD4-H524c
Human
Recombinant human CD74 / DHLAG Protein

CD74 分子别名

CD74,DHLAG,HLADG,II,Ia-GAMMA,p33,CLIP,INVG34

CD74 分子背景

Cluster of Differentiation 74 (CD74) is also known as HLA class II histocompatibility antigen gamma chain (HLADG), DHLAG, Ia-GAMMA, invariant chain (Abbreviated Ii). CD74 / HLADG is a polypeptide involved in the formation and transport of MHC class II protein. The cell surface form of the invariant chain is known as CD74. CD74 is upregulated in several cancers and is also expressed by non-immune cells during inflammation. CD74 plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha / beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal / lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. CD74 / DHLAG also serves as cell surface receptor for the cytokine MIF.

CD74 参考文献

CD74临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
ANG-1007 (AngioChem) ANG-3201; ANG-1007; ANG-1009; ANG-1011; ANG-2002; ANG-2004; ANG-2008; ANG-3101; ANG-3202; ANG-4043 临床前 AngioChem 癌症
SGN-15 BMS-182248; BMS-182248-01; BR96-DOX; SGN-15; hBR96 临床二期 百时美施贵宝, Seattle Genetics 非小细胞肺癌, 前列腺癌, 乳腺癌, 结肠直肠癌, 卵巢癌 详情
Milatuzumab hCD74; hLL1; IMMU-115,HCD-74 临床二期 Immunomedics 慢性淋巴细胞白血病, 移植物抗宿主病, 多发性骨髓瘤, 系统性红斑狼疮, 非霍奇金淋巴瘤 详情
Monoclonal antibody LYM-1-I-131 临床二期 西北大学, Peregrine, Schering Pharma 非霍奇金淋巴瘤
Apolizumab 临床二期 PDL BioPharma 实体瘤, 非霍奇金淋巴瘤 详情
Milatuzumab doxorubicin CD-74-DOX; hCD74-DOX; hLL1-DOX; IMMU-110 临床二期 Immunomedics 慢性淋巴细胞白血病, 多发性骨髓瘤, 非霍奇金淋巴瘤 详情
IMMU-114 IMMU-114; hL243 临床一期 Immunomedics 慢性淋巴细胞白血病, 非霍奇金淋巴瘤 详情
Anti-CD 74 antibody drug conjugates(Sutro Biopharma) STRO-001 临床一期 Sutro Biopharma 多发性骨髓瘤, 淋巴瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定